A promising vaccine strategy for the treatment of cancer involves the use of vaccines incorporating tumor antigenderived synthetic peptides that can be coordinately recognized by specific CD4C and CD8 C T-cells. Previously, we reported that a MAGE-A6-derived peptide (MAGE-A6 172-187 ) and its highly-immunogenic and cross-reactive homolog derived from Mycoplasma penetrans HF-2 permease (HF-2 216-229 ) are promiscuously presented by multiple HLA-DR alleles to responder CD4 C T-cells obtained from healthy donors and melanoma patients. Here, we investigated whether these same peptides could concomitantly stimulate cross-reactive MAGE-A6-specific CD8C T-cell responses in vitro using cells isolated from HLA-A*0201 (HLA-A2)C healthy individuals and patients with melanoma. We now show that MAGE-A6 172-187 and, even more so, HF-2 216-229 , induce memory CD8 C T cells that recognize HLA-A2 C MAGE-A6 C tumor target cells. The immunogenicity of these peptides was at least partially attributed to their embedded MAGE-A6 176-185 and HF-2 220-229 "homologous" sequences. The functional avidity of HF-2 216-229 peptide-primed CD8 C T cells for the MAGE-A6 172-187 peptide was more than 100-fold greater than that of CD8 C T cells primed with the corresponding MAGE-A6 peptide. Additionally, these 2 peptides were recognized in interferon g (IFNg) and granzyme B ELISPOT assays by CD8C T-cell clones displaying variable T-cell receptor (TCR) Vb usage. These data suggest that the immune crossreactivity of the MAGE-A6 172-187 and HF-2 216-229 peptides extends to CD8 C T cells, at least in HLA-A2 C donors, and supports the potential translational utility of these epitopes in clinical vaccine formulations and for immunomonitoring of cancer patients.